Literature DB >> 28265681

Ischemia-induced Drp1 and Fis1-mediated mitochondrial fission and right ventricular dysfunction in pulmonary hypertension.

Lian Tian1, Monica Neuber-Hess1, Jeffrey Mewburn1, Asish Dasgupta1, Kimberly Dunham-Snary1, Danchen Wu1, Kuang-Hueih Chen1, Zhigang Hong1, Willard W Sharp2, Shelby Kutty3, Stephen L Archer4.   

Abstract

Right ventricular (RV) function determines prognosis in pulmonary arterial hypertension (PAH). We hypothesize that ischemia causes RV dysfunction in PAH by triggering dynamin-related protein 1 (Drp1)-mediated mitochondrial fission. RV function was compared in control rats (n = 50) versus rats with monocrotaline-induced PAH (MCT-PAH; n = 60) both in vivo (echocardiography) and ex vivo (RV Langendorff). Mitochondrial membrane potential and morphology and RV function were assessed before or after 2 cycles of ischemia-reperfusion injury challenge (RV-IR). The effects of Mdivi-1 (25 μM), a Drp1 GTPase inhibitor, and P110 (1 μM), a peptide inhibitor of Drp1-Fis1 interaction, were studied. We found that MCT caused RV hypertrophy, RV vascular rarefaction, and RV dysfunction. Prior to IR, the mitochondria in MCT-PAH RV were depolarized and swollen with increased Drp1 content and reduced aconitase activity. RV-IR increased RV end diastolic pressure (RVEDP) and mitochondrial Drp1 expression in both control and MCT-PAH RVs. IR depolarized mitochondria in control RV but did not exacerbate the basally depolarized MCT-PAH RV mitochondria. During RV IR mdivi-1 and P110 reduced Drp1 translocation to mitochondria, improved mitochondrial structure and function, and reduced RVEDP. In conclusion, RV ischemia occurs in PAH and causes Drp1-Fis1-mediated fission leading to diastolic dysfunction. Inhibition of mitochondrial fission preserves RV function in RV-IR. KEY MESSAGES: Right ventricular ischemia reperfusion (RV-IR) causes RV diastolic dysfunction. IR-induced mitochondrial fission causes RV diastolic dysfunction. In RV-IR Drp1 translocates to mitochondria, binds Fis1 and causes fission and injury. A baseline RV mitochondriopathy in MCT PAH resembles IR-induced mitochondrial injury. Drp1 inhibitors (Mdivi-1 and P110) preserve RV diastolic function post RV-IR.

Entities:  

Keywords:  Diastolic dysfunction; Ischemia-reperfusion injury; Mdivi-1; Mitochondrial division inhibitor 1; Mitochondrial membrane potential; Pulmonary arterial hypertension

Mesh:

Substances:

Year:  2017        PMID: 28265681      PMCID: PMC5390778          DOI: 10.1007/s00109-017-1522-8

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  39 in total

1.  Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A consensus statement from the International Liaison Committee on Resuscitation (American Heart Association, Australian and New Zealand Council on Resuscitation, European Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Asia, and the Resuscitation Council of Southern Africa); the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; and the Stroke Council.

Authors:  Robert W Neumar; Jerry P Nolan; Christophe Adrie; Mayuki Aibiki; Robert A Berg; Bernd W Böttiger; Clifton Callaway; Robert S B Clark; Romergryko G Geocadin; Edward C Jauch; Karl B Kern; Ivan Laurent; W T Longstreth; Raina M Merchant; Peter Morley; Laurie J Morrison; Vinay Nadkarni; Mary Ann Peberdy; Emanuel P Rivers; Antonio Rodriguez-Nunez; Frank W Sellke; Christian Spaulding; Kjetil Sunde; Terry Vanden Hoek
Journal:  Circulation       Date:  2008-10-23       Impact factor: 29.690

2.  Adrenergic influence in the coronary circulation of conscious dogs during maximal vasodilation with adenosine.

Authors:  G J Vlahakes; R W Baer; P N Uhlig; E D Verrier; J D Bristow; J I Hoffmann
Journal:  Circ Res       Date:  1982-09       Impact factor: 17.367

3.  Constitutive Reprogramming of Fibroblast Mitochondrial Metabolism in Pulmonary Hypertension.

Authors:  Lydie Plecitá-Hlavatá; Jan Tauber; Min Li; Hui Zhang; Amanda R Flockton; Soni Savai Pullamsetti; Prakash Chelladurai; Angelo D'Alessandro; Karim C El Kasmi; Petr Ježek; Kurt R Stenmark
Journal:  Am J Respir Cell Mol Biol       Date:  2016-07       Impact factor: 6.914

4.  A selective inhibitor of drp1, mdivi-1, increases retinal ganglion cell survival in acute ischemic mouse retina.

Authors:  Sang Woo Park; Keun-Young Kim; James D Lindsey; Yi Dai; Hwan Heo; Duy H Nguyen; Mark H Ellisman; Robert N Weinreb; Won-Kyu Ju
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-04-27       Impact factor: 4.799

5.  Cardiac glutaminolysis: a maladaptive cancer metabolism pathway in the right ventricle in pulmonary hypertension.

Authors:  Lin Piao; Yong-Hu Fang; Kishan Parikh; John J Ryan; Peter T Toth; Stephen L Archer
Journal:  J Mol Med (Berl)       Date:  2013-06-21       Impact factor: 4.599

6.  Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension.

Authors:  Glenn Marsboom; Peter T Toth; John J Ryan; Zhigang Hong; Xichen Wu; Yong-Hu Fang; Thenappan Thenappan; Lin Piao; Hannah J Zhang; Jennifer Pogoriler; Yimei Chen; Erik Morrow; E Kenneth Weir; Jalees Rehman; Stephen L Archer
Journal:  Circ Res       Date:  2012-04-17       Impact factor: 17.367

7.  Right coronary autoregulation in conscious, chronically instrumented dogs.

Authors:  X Bian; A G Williams; P A Gwirtz; H F Downey
Journal:  Am J Physiol       Date:  1998-07

8.  A dynamic and chamber-specific mitochondrial remodeling in right ventricular hypertrophy can be therapeutically targeted.

Authors:  Jayan Nagendran; Vikram Gurtu; David Z Fu; Jason R B Dyck; Al Haromy; David B Ross; Ivan M Rebeyka; Evangelos D Michelakis
Journal:  J Thorac Cardiovasc Surg       Date:  2008-05-23       Impact factor: 5.209

9.  Mff is an essential factor for mitochondrial recruitment of Drp1 during mitochondrial fission in mammalian cells.

Authors:  Hidenori Otera; Chunxin Wang; Megan M Cleland; Kiyoko Setoguchi; Sadaki Yokota; Richard J Youle; Katsuyoshi Mihara
Journal:  J Cell Biol       Date:  2010-12-13       Impact factor: 10.539

10.  Dephosphorylation by calcineurin regulates translocation of Drp1 to mitochondria.

Authors:  G M Cereghetti; A Stangherlin; O Martins de Brito; C R Chang; C Blackstone; P Bernardi; L Scorrano
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-06       Impact factor: 11.205

View more
  35 in total

Review 1.  Mitochondrial dynamics and their potential as a therapeutic target.

Authors:  B N Whitley; E A Engelhart; S Hoppins
Journal:  Mitochondrion       Date:  2019-06-19       Impact factor: 4.160

2.  Mitochondrial Dysfunction: Metabolic Drivers of Pulmonary Hypertension.

Authors:  Hagir B Suliman; Eva Nozik-Grayck
Journal:  Antioxid Redox Signal       Date:  2019-02-25       Impact factor: 8.401

Review 3.  Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension.

Authors:  Ping Yu Xiong; Francois Potus; Winnie Chan; Stephen L Archer
Journal:  Hypertension       Date:  2017-11-20       Impact factor: 10.190

Review 4.  Mitochondrial quality control in cardiac cells: Mechanisms and role in cardiac cell injury and disease.

Authors:  Farzaneh G Tahrir; Dianne Langford; Shohreh Amini; Taha Mohseni Ahooyi; Kamel Khalili
Journal:  J Cell Physiol       Date:  2018-11-11       Impact factor: 6.384

Review 5.  Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles.

Authors:  Massimo Bonora; Mariusz R Wieckowski; David A Sinclair; Guido Kroemer; Paolo Pinton; Lorenzo Galluzzi
Journal:  Nat Rev Cardiol       Date:  2019-01       Impact factor: 32.419

Review 6.  Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountains.

Authors:  Miranda K Culley; Stephen Y Chan
Journal:  J Clin Invest       Date:  2018-08-06       Impact factor: 14.808

7.  Supra-coronary aortic banding improves right ventricular function in experimental pulmonary arterial hypertension in rats by increasing systolic right coronary artery perfusion.

Authors:  Lian Tian; Ping Yu Xiong; Elahe Alizadeh; Patricia D A Lima; François Potus; Jeffrey Mewburn; Ashley Martin; Kuang-Hueih Chen; Stephen L Archer
Journal:  Acta Physiol (Oxf)       Date:  2020-05-17       Impact factor: 6.311

8.  Epigenetic Metabolic Reprogramming of Right Ventricular Fibroblasts in Pulmonary Arterial Hypertension: A Pyruvate Dehydrogenase Kinase-Dependent Shift in Mitochondrial Metabolism Promotes Right Ventricular Fibrosis.

Authors:  Lian Tian; Danchen Wu; Asish Dasgupta; Kuang-Hueih Chen; Jeffrey Mewburn; Francois Potus; Patricia D A Lima; Zhigang Hong; Yuan-Yuan Zhao; Charles C T Hindmarch; Shelby Kutty; Steeve Provencher; Sebastien Bonnet; Gopinath Sutendra; Stephen L Archer
Journal:  Circ Res       Date:  2020-03-27       Impact factor: 17.367

9.  Regulation of mitochondrial fragmentation in microvascular endothelial cells isolated from the SU5416/hypoxia model of pulmonary arterial hypertension.

Authors:  Karthik Suresh; Laura Servinsky; Haiyang Jiang; Zahna Bigham; Joel Zaldumbide; John C Huetsch; Corrine Kliment; Michelle G Acoba; Brian J Kirsch; Steven M Claypool; Anne Le; Mahendra Damarla; Larissa A Shimoda
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-08-28       Impact factor: 5.464

10.  Epigenetic Dysregulation of the Dynamin-Related Protein 1 Binding Partners MiD49 and MiD51 Increases Mitotic Mitochondrial Fission and Promotes Pulmonary Arterial Hypertension: Mechanistic and Therapeutic Implications.

Authors:  Kuang-Hueih Chen; Asish Dasgupta; Jianhui Lin; François Potus; Sébastien Bonnet; James Iremonger; Jennifer Fu; Jeffrey Mewburn; Danchen Wu; Kimberly Dunham-Snary; Anne L Theilmann; Zhi-Cheng Jing; Charles Hindmarch; Mark L Ormiston; Allan Lawrie; Stephen L Archer
Journal:  Circulation       Date:  2018-02-05       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.